GSK (LON:GSK) Stock Rating Reaffirmed as “Hold” by Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating reaffirmed by stock analysts at Deutsche Bank Aktiengesellschaft in a report issued on Tuesday, September 29th, Digital Look reports. They presently have a GBX 2,000 price objective on the stock. Deutsche Bank Aktiengesellschaft’s price objective would indicate a potential upside of 13.28% from the stock’s current price.

Several other analysts also recently weighed in on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 price target on shares of GSK in a research note on Wednesday, July 29th. Berenberg Bank increased their price objective on GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research note on Tuesday, September 15th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a GBX 1,975 price objective on shares of GSK in a report on Tuesday, September 8th. Two research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of GBX 2,064.38.

GSK Trading Up 0.4%

Shares of LON GSK traded up GBX 6.50 during mid-day trading on Tuesday, reaching GBX 1,765.50. The company had a trading volume of 5,101,024 shares, compared to its average volume of 12,713,396. The stock has a market cap of £70.74 billion, a price-to-earnings ratio of 14.99, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. GSK has a 52 week low of GBX 1,592 and a 52 week high of GBX 2,282. The business’s 50-day moving average is GBX 1,875.68 and its 200-day moving average is GBX 1,938.58. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36.

GSK (LON:GSK) last announced its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Equities analysts expect that GSK will post 175.980975 earnings per share for the current year.

Insider Transactions at GSK

In other news, insider Anne Beal purchased 637 shares of the stock in a transaction dated Friday, September 18th. The shares were acquired at an average cost of GBX 4,985 per share, for a total transaction of £31,754.45. Also, insider Jonathan Symonds acquired 1,500 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was purchased at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Insiders bought a total of 2,144 shares of company stock worth $6,009,566 over the last 90 days. Company insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.